Publications by authors named "Y Yoneoka"
Tamoxifen, a common adjuvant therapy for hormone receptor-positive breast cancer, is associated with an increased risk of endometrial pathologies, such as hyperplasia, polyps, and carcinoma. This study investigates rapamycin, an mTOR inhibitor, as a potential novel strategy for preventing tamoxifen-induced endometrial proliferation. This in vitro study utilised endometrial stromal cells isolated from infertile women.
View Article and Find Full Text PDFObjectives: Higher body mass index (BMI) is reportedly associated with improved prognosis of patients with various cancers. However, it is unclear whether this phenomenon, also known as the obesity paradox, applies to metastatic renal cell carcinoma (mRCC). We aimed to determine the prognostic significance of BMI in patients with mRCC receiving first-line therapies.
View Article and Find Full Text PDFArticle Synopsis
- * Methods: Researchers reviewed medical records of patients treated with either therapy between January 2013 and August 2023, focusing on comparing the outcomes and side effects.
- * Results: The LEN/PEM group showed significantly better progression-free survival rates (70.0% at 6 months) compared to the platinum chemotherapy group (27.3%), despite similar response rates; further research is needed to confirm these results.
Article Synopsis
- The CheckMate 274 trial found that adjuvant nivolumab is more effective than placebo in treating high-risk urothelial carcinoma (UC) after surgery, but real-world data from Japan on its safety and efficacy were lacking.
- In this retrospective study, 33 patients who received adjuvant nivolumab following surgery were evaluated, revealing some immune-related adverse events (irAEs), with 3 patients experiencing severe reactions and 8 needing to discontinue treatment due to side effects.
- The study reported a 1-year overall survival rate of 100%, with a disease-free survival rate of 70%, although careful patient selection is crucial for this postoperative therapy.
Many cases of primary aldosteronism (PA) in patients who developed hypokalemia-induced rhabdomyolysis and underwent adrenalectomy for aldosterone-producing adenoma (APA) have been reported; however, the immunohistopathological and molecular features remain unknown. We herein report the case of a 28-year-old woman with PA who presented with hypokalemia-induced rhabdomyolysis and underwent adrenalectomy for unilateral APA. An immunohistochemical analysis revealed that most adenoma cells were positive for steroidogenic enzymes, including CYP11B2.
View Article and Find Full Text PDF